Enhanced Protection Against Tuberculosis by Recombinant BCG-Ag85C
Author Information
Author(s): Ruchi Jain, Bappaditya Dey, Neeraj Dhar, Vivek Rao, Ramandeep Singh, Umesh D. Gupta, Katoch V. M., V. D. Ramanathan, Anil K. Tyagi
Primary Institution: Department of Biochemistry, University of Delhi South Campus, New Delhi, India
Hypothesis
Can recombinant BCG (rBCG85C) provide better protection against tuberculosis compared to the standard BCG vaccine?
Conclusion
The study demonstrates that rBCG85C offers superior and lasting protection against tuberculosis in guinea pigs compared to the standard BCG vaccine.
Supporting Evidence
- Immunization with rBCG85C resulted in a significant reduction in lung and spleen bacillary load compared to the standard BCG vaccine.
- rBCG85C provided superior protection even after a prolonged post-challenge period.
- The cytokine profile in rBCG85C immunized animals showed reduced pro-inflammatory cytokines and improved lung architecture.
Takeaway
Researchers created a new vaccine that helps guinea pigs fight tuberculosis better than the old vaccine. This new vaccine keeps them safe for a longer time.
Methodology
Guinea pigs were immunized with rBCG85C and then exposed to M. tuberculosis to evaluate the vaccine's protective efficacy by measuring bacillary load and pathological changes.
Potential Biases
Potential bias in the selection of animal models and the interpretation of immunological responses.
Limitations
The study was conducted in a guinea pig model, which may not fully replicate human responses to tuberculosis.
Participant Demographics
Female outbred guinea pigs (Dunkin Hartley strain) weighing 200–300 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website